Genmab — Maj 2021

[Plimsoller]

God morgen

[transalp]

Go morgen. Og go dag med Helge i mio klubben.

[Helge_LarsenPI-redaktør]

Video: Tæt på Scandion Oncology, Ascelia Pharma & Hansa.:
https://www.proinvestor.com/index.php?p=debat_1&postid=93476

[Helge_LarsenPI-redaktør]

Spørgsmål til Q&A på mandag er mere end velkommen. Jeg har kun 5 stk´s inde nu.

[E_L]

I assume this is MIM-8 / Novo Nordisk ? Orphan Designation
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=814121

[E_L]

apparantly Talquetamab
also got orphan designation in March (Teclistamab already got it last year)

[E_L]

EHA Late breaking Dara abstract - SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY - https://library.ehaweb.org/eha/2020/eha25th/303396/efstathios.kastritis.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.html?f=listing%3D1*browseby%3D4*sortby%3D2*media%3D3*ce_id%3D1766*search%3Ddaratumumab*marker%3D794

[E_L]

lol, no that is still the one from last year , 2020

[E_L]

EHA poster SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325259/rogier.mous.subcutaneous.epcoritamab.in.patients.with.relapsed.refractory.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab

[E_L]

DARATUMUMAB MAINTENANCE VS OBSERVATION, finaly - Conclusion
CASSIOPEIA part 2 interim analysis showed a significantly longer PFS with daratumumab maintenance vs OBS in transplant-eligible patients with NDMM. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324588/philippe.moreau.daratumumab.maintenance.vs.observation.in.patients.with.newly.html?f=listing%3D1*browseby%3D8*sortby%3D2*media%3D3*ce_id%3D2035*label%3D21988*ot_id%3D25572*search%3Ddaratumumab*marker%3D1285

[Bulder]

thx E L. What do you think of epco? Efficacy looks similar to glofitamab, but AE looks better. Best in class?

[Bulder]

Just a moment...

(www.onclive.com)

[GeorgeBest]

If you only look at patients receiving optimal dose of Epcoritamab (48 mg), isn’t the Epcoritamab data better then?

[Bulder]

Maybritt a little. But is it enough to be meaningfull?

[Bulder]

NBI opfører sig da noget pænere end øvrige us-inden.

[Bulder]

Inden

[Bulder]

Index

[Bulder]

Forpulede iPad

[Bulder]

... relativt

[Bulder]

Ipad er absolut forpulet. NBI er relativt velopdragen i dag.